Milica Markovic, PhD

Milica Markovic, PhDMilicaMarkovic_2021_crop.jpg

Laboratory of Howard E. Gendelman, MD

Durham Research Center 3030
985800 Nebraska Medical Center
Omaha, NE 68198-5800

Keywords: Pharmacology, Prodrug approach, Drug Delivery, Drug Analysis, Immunomodulation, Neuroprotection, Neurodegenerative diseases

Research interests
Representative publications
Dr. Markovic's biographical information

Research interests

My research interest focuses on developing novel immune control therapeutics which can induce neuroprotection in Parkinson's disease (PD) and Alzheimer’s disease (AD). Recent work from our laboratory has shown direct cause and effect relationships between modulating the immune system and achieving therapeutic gain in the signs and symptoms for PD. Peptides were developed that enable transformation of effector neurotoxic T cells into regulatory neuroprotective cells.  This is based on extensive prior research on the roles of innate and adaptive immunity in affecting disease pathobiology and evidence from animal studies to the clinic that they may be harnessed for therapeutic gain. However, peptides, by themselves have short half-life and limited biodistribution. We posit that we can overcome this by conversion into long-acting prodrugs.  The focus of my research is to develop prodrugs from peptides and bioactive drugs, which will be tested as neuroprotective strategies for PD and AD in experimental animal models and for human disease translation. The long-term goal of our research is to produce therapeutics designed to harness the immune system in order to slow or prevent neurodegenerative disease pathobiology.

Representative publications

  1. Markovic, M. Ben-Shabat, Dahan, A. Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products, Pharmaceutics 2020, 12(11):1031. PMID: 33137942
  2. Markovic, M. Zur, M. Ragatsky, I. Cvijic, S. Dahan, A. BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide, Pharmaceutics 2020, 12(12):E1175. PMID: 33276565
  3. Markovic, M. Ben-Shabat, Dahan, A. Computational Simulations to Guide Enzyme-Mediated Prodrug Activation, International Journal of Molecular Sciences 2020, 21(9):E3248. PMID: 32443905
  4. Markovic, M. Zur, M. Dahan A. Cvijic S. Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability, European Journal of Pharmaceutical Sciences, 2020, 152:105440. PMID: 32615260
  5. Manda, J.N.* Markovic, M.* Zimmermann, EM. Ben-Shabat, S. Dahan, A. Aponick, A. Phospholipid Cyclosporine Prodrugs Targeted at Inflammatory Bowel Disease (IBD) Treatment: Design, Synthesis, and in Vitro Validation, ChemMedChem, 2020, 15(17):1639-1644. *equal contribution. PMID: 32618133
  6. Markovic, M. Ben-Shabat, Aponick, A. Zimmermann, EM. Dahan, A. Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics, International Journal of Molecular Sciences 2020, 21(9):E3248. PMID: 32375338
  7. Markovic, M. Ben-Shabat, S. Keinan, S. Aponick, A. Zimmermann, EM. Dahan, A. Phospholipid-based prodrugs for colon targeted drug delivery: Experimental study and in-silico simulations, Pharmaceutics 2019, 11(4):186. PMID: 30995772
  8. Markovic, M. Ben-Shabat, S. Keinan, S. Aponick, A. Zimmermann, EM. Dahan, A. Molecular Modeling-Guided Design of Phospholipid-Based Prodrugs. International Journal of Molecular Sciences 2019, 20(9):2210. PMID: 31060339
  9. Markovic, M. Ben-Shabat, S. Keinan, S. Aponick, A. Zimmermann, EM. Dahan, A. Prospects and Challenges of Phospholipid-Based Prodrugs. Pharmaceutics 2018, 10(4):210. PMID: 30388756
  10. Markovic, M. Ben-Shabat, S. Aponick, A. Zimmermann, EM. and Dahan, A. Lipidic prodrug approach for improved oral drug delivery and therapy, Medicinal Research Reviews 2018, 39(2):579-607. PMID: 30320896

Additional publications in PubMed.

Dr. Markovic's biographical information

Return to top of page